Eli Lilly has nabbed a win in the first U.S. trial over claims of withdrawal symptoms linked to its blockbuster antidepressant, Cymbalta. With more trials on the way--and thousands of cases alleging that the drugmaker soft-pedaled on the drug's withdrawal symptoms--the early victory could score the Indianapolis drugmaker some leverage.
Eli Lilly scored a victory in the first U.S. trial over claims of withdrawal symptoms linked to its blockbuster antidepressant, Cymbalta, as a federal jury found the drugmaker was not responsible for side effects such as brain zaps and suicidal ideations in a patient who quit the med.
Earlier this year, a U.S. judge dealt Eli Lilly a stinging blow after refusing to toss out lawsuits claiming that the company downplayed withdrawal symptoms linked to its blockbuster antidepressant, Cymbalta. Now Lilly is facing the first U.S. trials over the claims, a critical moment as it attempts to disentangle itself from a raft of litigation.
A U.S. judge refused to toss out lawsuits claiming that Eli Lilly & Co. downplayed withdrawal symptoms associated with its blockbuster antidepressant Cymbalta. As Bloomberg reports, Lilly will now have to fight claims that it misled consumers about "brain zaps" and other side effects suffered by people trying to quit using the drug.
Eli Lilly found itself standing at the bottom of a steep slope this year, beleaguered by slumping sales and patent losses for two of its bestselling drugs. The Indianapolis, IN-based company is continuing on its downward spiral, reporting a 16% dip in revenue due to exclusivity losses on anti-depressant Cymbalta and osteoporosis drug Evista.
Eli Lilly said 2014 would be an extraordinarily challenging year, and judging from its second-quarter earnings, that prediction wasn't wrong. Lilly's revenue dropped 17% to $4.9 billion in the second quarter, largely because the company lost its patent protection on two of its biggest blockbusters: the anti-depressant Cymbalta, which once brought in nearly $5 billion in sales annually, and osteoporosis drug Evista, previously a $1-billion-a-year hit.
Eli Lilly's patent cliff has struck again, but some analysts found things weren't as bad as they expected when they surveyed the damage Thursday morning. Higher sales of other drugs offset much of the generic competition to newly off-patent Cymbalta, helping the pharma giant beat Wall Street's revenue forecasts by a long shot.
Cymbalta is going down. The question for Eli Lilly is how fast and how far. Last evening, the FDA approved more than a half-dozen generic versions of Cymbalta, the antidepressant that's now Lilly's top-selling drug.
Drugmakers see contract reps as an easy-come, easy-go approach to marketing. Hire up when times are busy and new drugs rolling; staff down when drugs go off patent or the cost-cutting police come calling. But contract reps have rights, too--and that's why a former Eli Lilly sales person is suing the company.
Meeting next year's minimum revenue goal of $20 billion will be "challenging," Eli Lilly says, and analysts are already speculating about "savage" cost cuts if R&D doesn't come through as Lilly hopes.